Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group. [electronic resource]
Producer: 20171208Description: E105-E107 p. digitalISSN:- 1096-8652
- Adenine -- analogs & derivatives
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Cardiovascular Diseases -- chemically induced
- Dose-Response Relationship, Drug
- Female
- France -- epidemiology
- Gastrointestinal Diseases -- chemically induced
- Hematologic Diseases -- chemically induced
- Humans
- Infections -- etiology
- Leukemia, Lymphocytic, Chronic, B-Cell -- drug therapy
- Male
- Molecular Targeted Therapy
- Piperidines
- Protein Kinase Inhibitors -- administration & dosage
- Pyrazoles -- administration & dosage
- Pyrimidines -- administration & dosage
- Salvage Therapy
- Treatment Outcome
No physical items for this record
Publication Type: Letter; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.